Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 3053-3060

  Cheung, Nai Kong V ^a   Kushner, Brian H ^a   Cheung, Irene Y ^a   Kramer, Kim ^a   Canete, Adela ^a   Gerald, William ^a   Bonilla, Mary Ann ^a   Finn, Ronald ^a   Yeh, Samuel J ^a   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; GANGLIOSIDE GD2; HERMES ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G3; IODINE 131; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; UNCLASSIFIED DRUG;

ADOLESCENT; AGE; ARTICLE; BONE MARROW METASTASIS; BONE MARROW TRANSPLANTATION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; PAIN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URTICARIA;

EID: 0031686971     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.3053     Document Type: Article

References (37)

1. Phillip T, Zucker JM, Bernard JL, et al: Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup? J Clin Oncol 9:1037-1044, 1991
2. Kushner BH, Cheung NK: Treatment of neuroblastoma, in DeVita V, Rosenberg S, Hellman S (eds): Updates, vol 2, February, no. 2: Cancer - Principles & Practice of Oncology (ed 2). Philadelphia, PA, Lippincott, 1988, pp 1-11
3. Cheung NK, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9:1050-1058, 1991
4. Cheung NK: Biological and molecular approaches to treatment immunotherapy, in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology (ed 2). Philadelphia, PA, Lippincott, 1992, pp 357-370
5. Wu Z, Schwartz E, Seeger RC, Ladisch S: Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 46:440-443, 1986
6. Gomibuchi M, Katano J, Saxton RE, et al: Human monoclonal antibody to tumor-associated ganglioside GD2: In vivo reactivity to human melanoma. Proc Am Assoc Cancer Res 25:248, 1984 (abstr)
7. Schulz G, Cheresh DA, Varki NM, et al: Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 44:5914-5920, 1984
8. Cheung NK, Saarinen UM, Neely JE, et al: Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45:2642-2649, 1985
9. Thurin J, Thurin M, Kimoto Y, et al: Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res 47:1229, 1987
10. Munn DH, Cheung NK: Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity (ADCC) against human melanoma. Cancer Res 47:6600-6605, 1987
11. Kushner BH, Cheung NK: GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 73:1936-1941, 1989
12. Munn DH, Cheung NK: Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. J Exp Med 172:231-237, 1990
13. Yeh SD, Larson SM, Burch L, et al: Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-Metaiodobenzylguanidine (MIBG) and standard diagnostic modalities. J Nucl Med 32:769-776, 1991
14. Miraldi FD, Nelson AD, Kraly C, et al: Diagnostic imaging of human neuroblastoma with radiolabeled antibody. Radiology 161:413-418, 1986
15. Cheung NKV, Walter EI, Smith-Mensah WH, et al: Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 81:1122-1128, 1988
16. Cheung NK, Lazarus H, Miraldi FD, et al: Ganglioside GD2 specific monoclonal antibody 3F8 - A phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5:1430-1440, 1987
17. Cheung NK, Lazarus H, Miraldi FD, et al: Reassessment of patient response to monoclonal antibody 3F8. J Clin Oncol 10:671-672, 1992
18. Cheung NKV, Kushner BH, Yeh SJ, et al: 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: A phase II study. Int J Oncol 12:1299-1306, 1998
19. Kushner BH, LaQuaglia MP, Bonilla MA, et al: Highly effective induction therapy for stage 4 neuroblastoma in children over one year of age. J Clin Oncol 12:2607-2613, 1994
20. Brodeur G, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 11:1466-1477, 1993
21. Cheung NK, Heller G, Kushner BH, et al: Detection of metastatic neuroblastoma in bone marrow: When is routine marrow histology insensitive? J Clin Oncol 15:2807-2817, 1997
22. Cheung NK, Cheung IY, Canete A, et al: Antibody response to murine anti-GD2 monoclonal antibodies: Correlation with patient survival. Cancer Res 54:2228-2233, 1994
23. Cheung IY, Cheung NKV: Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res 3:821-826, 1997
24. Kramer K, Cheung NKV, Gerald WL, et al: Correlation of N-myc amplification, TrkA and CD44 expression with clinical stage in 250 patients with neuroblastoma. Eur J Cancer 33:2098-2100, 1997
25. Ladenstein R, Favrot M, Lasset C, et al: Indication and limits of megatherapy and bone marrow transplantation in high-risk neuroblastoma: A single centre analysis of prognostic factors. Eur J Cancer 29A:947-956, 1993
26. Matthay KK, Seeger RC, Reynolds CP, et al: Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: A report from the Childrens Cancer Group. J Clin Oncol 12:2382-2389, 1994
27. Mugishima H, Iwata M, Okabe I, et al: Autologous bone marrow transplantation in children with advanced neuroblastoma. Cancer 74:972-977, 1994
28. Ladenstein R, Lasset C, Hartmann O, et al: Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: A report from the European Group for Bone Marrow Transplantation. J Clin Oncol 11:2330-2341, 1993
29. Saleh MN, Khazaeli MB, Wheeler RH, et al: A phase I trial of the murine monoclonal anti-GD2 antibody 14.G2a in metastatic melanoma. Cancer Res 52:4342-4347, 1992
30. Murray JL, Cunningham JE, Brewer H, et al: Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12:184-193, 1994
31. Yu AL, Gillies SD, Reisfeld RA: Phase I clinical trial of ch14.18 in patients with refractory neuroblastoma. Proc Am Soc Clin Oncol 10:318, 1991 (abstr)
32. Jerne NK: Toward a network theory of the immune system. Ann Immunol (Paris) 125C:373-389, 1974
33. Herlyn D, Lubeck M, Sears H, et al: Specific detection of anti-idiotypic immune response in cancer patients treated with murine monoclonal antibody. J Immunol Methods 85:27-38, 1985
34. Fagerberg J, Frodin JE, Wigzell H, Mellstedt H: Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab1) lead to tumor regression after mAb therapy? Cancer Immunol Immunother 37:264-270, 1993
35. Koprowski H, Herlyn D, Lubeck M, et al: Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci USA 81:216-219, 1984
36. Fagerberg J, Frodin JE, Ragnhammar P, et al: Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy? Cancer Immunol Immunother 38:149-159, 1994
37. Cheung NK, Canete A, Cheung IY, et al: Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int J Cancer 54:499-505, 1993